X
Keytruda combo set to become “standard of care” in kidney cancer
https://pharmaphorum.com/news/keytruda-combo-set-to-become-standard-of-care-kidney-cancer/
renal cell carcinoma
EU approves Ipsen’s Cabometyx in first line kidney cancer
Drug looks set to become core part of Ipsen’s cancer offering
NICE recommends Novartis kidney cancer drug
Afinitor finally recommended after rejection in 2011.
NICE does U-turn, backs Opdivo in kidney cancer
Price cut and new data sways NICE.
Ipsen/Exelixis’ drug approved in EU for kidney cancer
Cabometyx secures new indication in renal cell carcinoma.